Please login to the form below

Not currently logged in
Email:
Password:

Lilly Evista patents upheld

Eli Lilly has won a court victory that the company said will keep osteoporosis drug Evista protected from generic competition in the US until 2014

Eli Lilly has won a court victory that the company said will keep its blockbuster osteoporosis drug Evista (raloxifene) protected from generic competition in the US marketplace until March 2014.

In the ruling, the US Court of Appeals for the Federal Circuit upheld a 2009 decision by the US District Court for the Southern District of Indiana that the company's method-of-use patents for the drug are valid on all accounts, including the doctrines of obviousness, enablement, and inequitable conduct.

The patents had been challenged by Teva Pharmaceuticals, which has won tentative approval from the US Food and Drug Administration (FDA) for generic Evista but cannot launch the product until Lilly's patents expire or are deemed invalid.

Although the overall decision was a victory for Lilly, the appeals court also affirmed the district court's ruling that held Evista's particle-size patents invalid. Lilly said it would "review its legal options" regarding that part of the ruling.

Evista, which is used in the prevention of osteoporosis in postmenopausal women, brings in about $700m a year for Lilly. The drug is also cleared for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.

2nd September 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics